US pharma major Merck & Co (NYSE: MRK) has not previously been the noisiest of drug companies when talking about its work in COVID-19, but it now appears to be making up for this.
Following on from the announcement that it will acquire Themis, a privately-held company developing a vaccine candidate targeting SARS-CoV-2 for the prevention of COVID-19, Merck announced two further research programs to fight the virus.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze